 |
|
|
|
|
 |
|
|||
 |
 |
 |
|
|
 |
|
|||
NCI funds 17 Early Detection Research Network Biomarker Development Labs
The National Cancer Institute (NCI) has awarded $9.8 million in first
year funding for 17 Biomarkers Developmental Laboratories within the
Early Detection Research Network (EDRN). Biomarkers are substances found
in the blood, other body fluids, or tissues that—alone or in combination—may
signal the presence of cancer or the risk for cancer. The newly funded
laboratories role within the EDRN is to discover new biomarkers relevant
to major cancers and to identify what combinations of biomarkers may
best detect the presence or risk of cancer.
This award marks the second round of 5-year funding for components of
the Network. Of 68 applications received to be Biomarker Developmental
Laboratories, 22 were rated as excellent to outstanding and 17 were
selected for funding. About 40 percent of grantees are new to the network,
which began in 1999. New laboratories are noted in the chart below with
an asterisk (*).
The other components of the EDRN are Biomarker Validation Laboratories,
which work to validate the biomarker tests, Clinical and Epidemiologic
Centers, which conduct the early phases of clinical and epidemiological
research on the application of biomarkers, and the Data Management and
Coordinating Center which provides logistical, informatics, and statistical
development and support.
These new Biomarker Developmental Laboratories have one of the biggest
challenges in biomarker research: searching through hundreds of samples
using a variety of technologies to identify candidate biomarkers. These
investigators will examine the human genome (genetic material), proteome
(proteins made by genes), epitome (immune response biomarkers via antibody-antigen
patterns), and metabolome (metabolic pathways and regulation), looking
for potential ways to identify cancer and cancer risk.
For more information about cancer, visit the NCI Web site at www.cancer.gov
or call NCI's Cancer Information Service at 1-800-4- CANCER (1-800-422-6237).
NCI-funded Early Detection Research Network Biomarker Development Labs(alphabetic by last name) * = new grantee |
||||
| Principal Investigator |
Institution |
Organ Focus |
Technology Approach |
Industry Collaboration |
| William L. Bigbee, Ph.D. |
Univ of Pittsburgh Cancer Center |
Colon |
Proteomics |
Biospect |
| Timothy Block, Ph.D. |
Drexel Univ |
Liver |
Proteomics Glycomics |
Xenomics, Inc. Immunotype, Inc. |
| *Paul Cairns, Ph.D. |
Fox Chase Cancer Center |
Kidney |
Methylation, Proteomics |
-------- |
| *Arul Chinnaiyan, M.D., Ph.D. |
Univ of Michigan |
Prostate |
Genomics, Proteomics libraries and Immune Response |
GMP Companies, Inc. |
| Bogdan A. Czerniak, M.D., Ph.D. |
Univ of Texas/ M.D. Anderson Cancer Center |
Bladder |
Genomics |
-------- |
| *Laura J. Esserman, M.D., M.B.A. |
Univ of California, San Francisco |
Breast |
Genomics and Proteomics |
Sequenom, Biotrue, BD Biosciences, Celera Diagnostics, Biospect, ChromaVision |
| Wilbur A. Franklin, M.D. |
Univ of Colorado Health Science Center |
Lung |
Genomics |
-------- |
| Adi F. Gazdar, M.D. |
Univ of Texas Southwestern Medical Center |
Lung |
Genomics and Proteomics |
Rules-Based Medicine |
| Samir Hanash, M.D., Ph.D. |
Fred Hutchinson Cancer Research Center |
Lung and others |
Proteomics and AutoAbs |
-------- |
| *Michael Hollingsworth, Ph.D. |
Univ of Nebraska Medical Center |
Pancreas |
Proteomics and Mice Models |
-------- |
| *Anne M. Killary, Ph.D. |
Univ of Texas/M.D. Anderson Cancer Center |
Pancreas |
Genomics |
-------- |
| *Alvin Y. Liu, Ph.D. |
Univ of Washington |
Prostate and Bladder |
Proteomics |
MacroGenics Inc. |
| Jeffery R. Marks, Ph.D. |
Duke Univ Medical Center |
Breast |
Genomics (Gene Expression) Proteomics |
Abbott Laboratories Diagnostic Division |
| Stephen J. Meltzer, Ph.D. |
Univ of Maryland School of Medicine |
Esophagus |
Genomic and Proteomics |
-------- |
| *Hemant K. Roy, M.D. |
Evanston Northwestern Research Institute |
Colon |
Spectral imaging |
-------- |
| J. Oliver Semmes, Ph.D. |
Eastern Virginia Medical School |
Multi |
Proteomics |
Ciphergen |
| David Sidransky, Ph.D. |
Johns Hopkins Univ |
Lung |
Genomics |
Oncomethylome Sciences, Affymetrix |
about
us | current issue | archive
| home
E-mail us.